Approved · Waiver · decided in 20 days, 19 Nov 2026
Pemba Capital Partners, through Curis BidCo Pty Ltd, proposes to acquire 100% of the shares in Accelagen Pty Ltd. Accelagen is an Australian contract research organisation providing clinical development and regulatory affairs services to biotechnology, pharmaceutical, and medical device companies. This is a share acquisition by the private equity fund manager.
Curis BidCo Pty Ltd (BidCo) proposes to acquire 100% of the issued shares in Accelagen Pty Ltd (Accelagen) from Accelagen’s existing founding shareholders (the Acquisition). BidCo is a special purpose vehicle and is an indirect wholly owned subsidiary of Curis HoldCo Pty Ltd (HoldCo). HoldCo is currently wholly owned by Pemba Capital Fund IV, L.P., a private equity fund managed by Pemba Capital Partners Pty Ltd (Pemba), based in Sydney. The Acquisition will be implemented by way of a Share Purchase Deed. Following completion, BidCo will exercise control of Accelagen. Pemba is an investor in high-growth and entrepreneurial businesses, with over AUD 2 billion in assets under management. Pemba has interests across various sectors, including business services, education & training, financial services, healthcare, and technology. Accelagen is an Australian-based, full-service contract research organisation (CRO), with a focus on clinical development and regulatory affairs, providing guidance and support throughout all stages of product development to biotechnology, pharmaceutical and medical device companies, including the development, initiation and management of Phase I-IV clinical trials.